(Q34384108)

1 August 2017

1 reference

title

Pathophysiologic mechanisms of postprandial hyperglycemia (English)

1 reference

1 August 2017

1 reference

1 reference

Gavin JR 3rd

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

American Journal of Cardiology

1 August 2017

published in

1 reference

1 August 2017

volume

88

1 reference

1 August 2017

issue

6A

1 reference

1 August 2017

page(s)

4H-8H

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Carbohydrate metabolism in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

The postprandial state: mechanisms of glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Reversible insulin resistance in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Hexosamines and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Postprandial glucose and vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Negative consequences of glycation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Roles of the AGE-RAGE system in vascular injury in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Serum glucose concentration as a modulator of interdigestive gastric motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

The incretin concept today

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

‘Pharmacological Fibre’-Alpha-glucosidase Inhibition in the Management of Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901830-6

10.1016/S0002-9149(01)01830-6

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference